Kolexia
Kiladjian Jean-Jacques Hématologie
Kiladjian Jean-Jacques
Hématologie
Hôpital Saint-Louis
Paris, France
842 Activités
2.2 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélofibrose primitive Polyglobulie primitive essentielle Polyglobulie Thrombocytémie essentielle Syndromes myéloprolifératifs Thrombocytose Anémie Thrombopénie Thrombose

Collaborateurs

Voir plus
Cassinat Bruno
Cassinat Bruno
Hôpital Saint-Louis, Paris, France
Giraudier Stephane
Giraudier Stephane
Hôpital Saint-Louis, Paris, France
Ianotto Jean-Christophe
Ianotto Jean-Christophe
Hôpital Morvan, Brest, France
Boyer Francoise
Boyer Francoise
Hôpital Larrey Angers, Angers, France

Industries

Voir plus
Novartis
109 collaboration(s)
Dernière en 2023
Abbvie
34 collaboration(s)
Dernière en 2023
Celgene
16 collaboration(s)
Dernière en 2022
GSK
10 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
MANIFEST-2: A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Essai Clinique (Constellation Pharmaceuticals)   14 mars 2024
INDEPENDENCE: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Essai Clinique (Celgene)   06 mars 2024
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis: A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis and Essential Thrombocytopenia)
Essai Clinique (Constellation Pharmaceuticals)   05 mars 2024
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Annals of hematology   04 mars 2024
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment: A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor
Essai Clinique (Geron Corporation)   28 février 2024
PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA)
Essai Clinique (CTI BioPharma)   16 février 2024
Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloprolifératifs.
Haematologica   08 février 2024
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
EJHaem   05 février 2024
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research   02 février 2024
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM.
American journal of hematology   26 janvier 2024